Hospital Clínic de Barcelona
Barcelona, Spain
Location status: Recruiting
Location contact
Andreu Porta, MD PhD
PRINCIPAL_INVESTIGATOR
Manuel Castellà, MD PhD
CONTACT
Nuria Pichel, MSc
CONTACT
NCT Number: NCT05723536
In patients with symptomatic atrial fibrillation (AF), current clinical guidelines recommend ablation for rhythm control.
While percutaneous ablation has good results in patients with paroxysmal AF, it is not clear which is the best technique in patients with persistent or long-standing persistent AF. Our group performed the first randomized study of thoracoscopic epicardial ablation vs. endocardial catheter ablation (FAST Trial), which showed better results for epicardial ablation but with a higher rate of complications. Hybrid epicardial and endocardial ablation strategies have recently been described sequentially, showing better results in patients with persistent AF, but 40% of patients are still refractory to ablation.
Our study aims to compare the conventional strategy (catheter ablation) with partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) in a single procedure in the group of patients most refractory to ablation. Likewise, using magnetic resonance imaging and echocardiography to analyze the atrial remodeling factors that can predict the success and failure of both therapies.
Methodology: A 1:1 randomized clinical trial in patients with persistent and long-standing persistent AF in two groups: conventional ablation vs. partial endo-epicardial isolation. Prior to ablation, cardioversion will be performed and functionality and atrial size will be verified by echocardiography, delayed-enhancement / 4D flow magnetic resonance imaging (MRI), andelectrocardiographic imaging (ECGi) will detect the degree of fibrosis and atrial remodeling. During the ablation procedure, a continuous rhythm recording device will be implanted. Likewise, at three months the MRI will be repeated to detect post-ablation fibrosis. At six months the echocardiography will be performed to assess atrial function and size. AF recurence will be assessed using an internal loop recorder within a 1-year follow-up.
Main Expected Results: The expected results include: 1. an improvement in the rate of patients with no atrial arrhythmias recurrence in patients undergoing endo-epicardial ablation; 2. a lower AF burden in patients undergoing endo-epicardial ablation who have had recurrence; 3. To know the degree of atrial remodeling (including atrial fibrosis) associated with the success/failure of each technique; 4. To know the degree of fibrosis that both techniques produce; 5. To know the degree of ventricular function associated with the success/failure of each technique; 6. To know the degree of potentially lost atrial function; 7. To Compare the safety of both techniques
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Barcelona, Spain
Location status: Recruiting
Andreu Porta, MD PhD
PRINCIPAL_INVESTIGATOR
Manuel Castellà, MD PhD
CONTACT
Nuria Pichel, MSc
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
Endocavity catheter ablation of persistent atrial fibrillation : pulmonary vein isolation and posterior wall isolation
Time frame: 3-12 months post-surgery
Success or failure to be free of atrial arrhythmias (AF/AT/AFL) in the absence of class I and III antiarrhythmic drugs, or with the same antiarrhythmic treatment prior to study inclusion, after the 3-month blank period, during 12 months after the procedure and measured by internal loop recorder.
Time frame: 3-12 months post-surgery
90% reduction in baseline AF burden in the absence of a new/increased dose of class I/III antiarrhythmic medication, as measured by implantable ECG recorder.
Time frame: 3-months pre-surgery to 12 months post-surgery
Pre-procedure atrial remodelling by MRI measuring fibrosis grade. Pre-procedure atrial remodelling by echocardiogram measuring size and function. Pre-procedure assessment of electrical atrial remodeling in AF and sinus rhythm using ECGi. Both measurements are in relation to primary endpoint success/failure in both groups.
Time frame: 3-12 months post-surgery
Post-procedure atrial remodelling by MRI measuring fibrosis grade. Post-procedure atrial remodelling by echocardiogram measuring size and function. Both measurements are in relation to primary endpoint success/failure in both groups.
Contact information is provided by the study sponsor or research team.
Manuel Castellà, MD PhD
CONTACT
Nuria Pichel, MSc
CONTACT
Hospital Clinic of Barcelona
Other
Acronym: PLAI-AF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03231826
Arrhythmias, Cardiac, Arrythmia
Tampere, Pirkanmaa, Finland
View Trial DetailsNCT04962932
Arrhythmias, Cardiac, Arrythmia
Solna, Sweden
View Trial DetailsNCT05226416
Anemia, Arrhythmias, Cardiac
Moscow, Russia
View Trial DetailsNCT05103579
Arrhythmias, Cardiac, Arrythmia
Sumter, South Carolina, United States
View Trial Details